108 Consolidated Changes in Equity 1,000 chf share capital Attributable to equity holders of <strong>Sonova</strong> Holding AG share premium Retained earnings translation adjustment treasury shares hedge reserve non controlling interests Balance April 1, 2009 3,312 72,703 1,100,064 (81,814) (72,397) 0 4,755 1,026,623 Income for the period (published) 354,457 356 354,813 adjustments (137,239) (942) (138,181) Income for the period (restated) 217,218 (586) 216,632 other comprehensive income (published) 19,966 33,956 (2,057) 229 52,094 adjustments other comprehensive income (7,617) (52) (7,669) (restated) Total comprehensive income 19,966 26,339 (2,057) 177 44,425 (published) 374,423 33,956 (2,057) 585 406,907 adjustments (137,239) (7,617) (994) (145,850) Total comprehensive income (restated) 237,184 26,339 (2,057) (409) 261,057 Balance March 31, <strong>2010</strong> (published) 3,305 60,649 1,409,099 (47,858) (20,812) (2,057) 6,032 1,408,358 adjustments (137,239) (7,617) (994) (145,850) Balance March 31, <strong>2010</strong> (restated) 3,305 60,649 1,271,860 (55,475) (20,812) (2,057) 5,038 1,262,508 the following table reflects the impacts on the acquisition balance sheet of advanced Bionics in connection with the finalization of the initial accounting: Assets and liabilites acquired 1,000 chf 2009/10 2009/10 total equity Published adjustments Restated current assets 70,175 (19,891) 50,284 Property, plant and equipment <strong>11</strong>,186 (1,144) 10,042 Intangible assets 123,965 (56,763) 67,202 other noncurrent assets 1 1 current liabilities (38,309) (<strong>11</strong>,763) (50,072) noncurrent liabilities (10,052) (46,874) (56,926) Net assets 156,966 (136,435) 20,531 goodwill 347,494 136,435 483,929 Purchase consideration 504,460 0 504,460 Cash consideration 504,460 0 504,460 cash and cash equivalents acquired (3,589) 0 (3,589) Cash consideration, net of cash acquired 500,871 0 500,871
4. changes in group structure consolidated financial statements 109 in the financial year <strong>2010</strong>/<strong>11</strong> the group entered into several business combinations which were individually not significant. the companies acquired are in the business of distributing hearing instruments. while in most of the acquisitions 100% of the share capital was acquired, the group also entered into three business combinations where the group previously held an equity investment (step up acquisitions). for these acquisitions, the previously held equity share was revalued to fair value, considering any fair value adjustments in the income statements (included in financial result). in addition to the companies acquired, the group established new sales organizations in the hearing implant business in turkey (aB turkey) and australia (aB australia) and in the hearing instrument business in taiwan (Phonak taiwan). in the financial year 2009/10 the group entered into two main business combinations, acquiring in each case 100% of the share capital. as of december 30, 2009, the group acquired advanced Bionics corporation, ca, usa. advanced Bionics is a global leader in developing and manufacturing cochlear implant systems. as of January 6, <strong>2010</strong>, the group acquired insound medical inc., newark, usa. insound medical is the manufacturer of lyric, an innovative, totally invisible, extendedwear hearing solution for those with mild to moderate hearing loss. insound medical has commercially marketed lyric in the u.s. since 2008. in addition, the group acquired several small entities which are in the business of distributing hearing instruments. the effect of the acquisitions for the financial year <strong>2010</strong>/<strong>11</strong> and 2009/10 is disclosed in note 27.
- Page 1 and 2:
THE HEARING CARE COMPANY All the So
- Page 3 and 4:
highLightS & Key figureS - New sale
- Page 5 and 6:
02 Foreword 06 Sonova Group 16 Hear
- Page 7 and 8:
from 2002 to 2004 and subsequently
- Page 9 and 10:
eaKinG barrierS - with talent and t
- Page 11 and 12:
ON THE WAY TO BECOMING A GLOBAL HEA
- Page 13 and 14:
and a global distribution network e
- Page 15 and 16:
THE SONOVA GROUP No hearring loosss
- Page 17 and 18:
Better hearing for people with norm
- Page 19 and 20:
StraiGHt From real liFe - cowboy ha
- Page 21 and 22:
THE HEARING INSTRUMENT MARKET - CON
- Page 23 and 24:
THE PHONAK SPICE GENERATION - THE S
- Page 25 and 26:
WIDE RANGE OF HEARING INSTRUMENTS T
- Page 27 and 28:
LYRIC - THE “CONTACT LENS FOR THE
- Page 29 and 30:
Sonova is investing heavily in the
- Page 31 and 32:
Eight years later, Evelyn almost co
- Page 33 and 34:
THE HEARING IMPLANTS SEGMENT In the
- Page 35 and 36:
The considerable strategic importan
- Page 37 and 38:
ABOUT ADVANCED BIONICS Advanced Bio
- Page 39 and 40:
worKinG - and communicating safely
- Page 41 and 42:
EMPLOYEES FOCUS ON PEOPLE One of th
- Page 43 and 44:
ISO 9001:2000 and 13485:2003 certif
- Page 45 and 46:
The key environmental data shown in
- Page 47 and 48:
ENVIRONMENTAL MANAGEMENT AT THE ST
- Page 49 and 50:
CAMBODIA - BETTER OPPORTUNITIES FOR
- Page 51 and 52:
Better hearing - better success at
- Page 53 and 54:
in critical moments. As a consequen
- Page 55 and 56:
CrOSS-SHArEHOLDInGS Sonova Holding
- Page 57 and 58:
BOArD Of DIrECTOrS The primary duty
- Page 59 and 60:
Andy rihs Co-founder, non-executive
- Page 61 and 62: onald van der Vis non-executive mem
- Page 63 and 64: AuDIT COMMITTEE The members of the
- Page 65 and 66: Alexander Zschokke Interim CEO, GVP
- Page 67 and 68: Dr Hans Leysieffer GVP research & D
- Page 69 and 70: COmPenSatiOn and SharehOldingS - co
- Page 71 and 72: The shares/rSus have a blocking per
- Page 73 and 74: COMPEnSATIOn TO MEMBErS Of THE MAnA
- Page 75 and 76: SHArEHOLDInGS Of MEMBErS Of THE BOA
- Page 77 and 78: The following table shows the detai
- Page 79 and 80: CHAnGES Of COnTrOL AnD DEfEnSE MEAS
- Page 81 and 82: COMPEnSATIOn rEPOrT inveStOrS at SO
- Page 83: develOPing SPeeCh CaPaBilitieS - mo
- Page 86 and 87: 82 Financial Review - setting the c
- Page 88 and 89: 84 SALES in CHF m EBITA in CHF m 1,
- Page 90 and 91: 86 SUBSTANTIAl INVESTMENTS IN INNoV
- Page 92 and 93: 88 AdVANCEd BIoNICS RESUMES SAlES I
- Page 94 and 95: 90 5 year key Figures (Consolidated
- Page 96 and 97: 92 Consolidated Income Statements 1
- Page 98 and 99: 94 Consolidated Cash Flow Statement
- Page 100 and 101: 96 NoTeS To THe CoNSoLIdATed FINANC
- Page 102 and 103: 98 INveSTMeNTS IN JoINT veNTuReS In
- Page 104 and 105: 100 LeASING Assets that are held un
- Page 106 and 107: 102 SeGMeNT RePoRTING operating seg
- Page 108 and 109: 104 3.5 derivative financial instru
- Page 110 and 111: 106 3.7 Restatement of prior year
- Page 114 and 115: 110 5. segment information segment
- Page 116 and 117: 112 6. other expenses, net 1,000 ch
- Page 118 and 119: 114 Deferred tax assets and (liabil
- Page 120 and 121: 116 11. cash and cash equivalents 1
- Page 122 and 123: 118 14. other receivables and prepa
- Page 124 and 125: 120 the increase in property, plant
- Page 126 and 127: 122 1,000 cHf 31.3.2010 Cost Goodwi
- Page 128 and 129: 124 20. Provisions 1,000 cHf 31.3.2
- Page 130 and 131: 126 23. non-current financial liabi
- Page 132 and 133: 128 foreign currency sensitivity an
- Page 134 and 135: 130 the following table summarizes
- Page 136 and 137: 132 caPital RisK manaGement it is t
- Page 138 and 139: 134 the annual General shareholders
- Page 140 and 141: 136 28. Related party transactions
- Page 142 and 143: 138 Amounts recognized in the incom
- Page 144 and 145: 140 30. Employee share option and s
- Page 146 and 147: 142 The fair value of options/warra
- Page 148 and 149: 144 Changes in outstanding shares/R
- Page 150 and 151: 146 36. list of significant consoli
- Page 152 and 153: 148 REPORT OF THE STATuTORY AuDITOR
- Page 154 and 155: 150 Income Statements 1,000 CHF Not
- Page 156 and 157: 152 NOTES TO THE FINANCIAL STATEmEN
- Page 158 and 159: 154 Executive Equity Award Plan The
- Page 160 and 161: 156 Compensation to the management
- Page 162 and 163:
158 The following table shows the d
- Page 164 and 165:
160 Warrants EEAP 10 2) Warrants/ o
- Page 166 and 167:
162 Company name Activity Domicile
- Page 168 and 169:
164 Appropriation of Available Earn
- Page 170 and 171:
166 REPORT OF THE STATUTORy AUDITOR
- Page 173 and 174:
Disclaimer This report contains for